Neurizon Therapeutics
Neurizon confirms positive results for prospective ALS treatment
June 23, 2025Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
